Antibiotic Pharmacokinetics
Conditions
Brief summary
The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.
Interventions
DRUGPiperacillin/tazobactam, Meropenem
This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
Sponsors
Karolinska University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patient being treated in one of the participating ICUs and planned to recieve treatment with meropenem or piperacillin.
Exclusion criteria
(fullfilling any exlusion criteria means that patient cannot be included in the study): * Not possible to retrospectively ask the patient or next of kin for consent to take part in the study or patient or next-of-kin not providing consent. * Not posisble to obtain and process blood samples as specified by protocol. * Ongoing renal replacement therapy. * Patient having received the same antibiotic within the previous 96 h.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume of distribution | For the first antibiotic administration and if possible for a second administration 48-72 hour later. | Apparent volume of distribution calculated from repeated plasma concentrations measurements and pharmacokinetic modelling. |
| Plasma clearance | For the first antibiotic administration and if possible for a second administration 48-72 hour later. | Plasma clearance calculated from repeated plasma concentrations measurements and pharmacokinetic modelling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma antibiotic concentrations at mid and end of dosing interval | For the first antibiotic administration and if possible for a second administration 48-72 hour later. | Plasma antibiotic concentrations at mid and end of dosing interval |
Countries
Sweden
Contacts
Primary ContactJohan Petersson, MD, Ass Prof
Backup ContactErik Eliasson, MD, Prof
Outcome results
None listed